SCHEMBL7085589

SCHEMBL7085589

Cc1csc(-c2nc(C3(C)SCCCS3)[nH]c2-c2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.38
MAPK13 O15264 8/20 0.38
MAPK12 P53778 8/20 0.38
MAPK11 Q15759 8/20 0.38
GCGR P47871 5/20 0.38
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX5 P09917 1/20 0.34
MAPK9 P45984 2/20 0.33
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089424 0.78 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7085587 0.77 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7090773 0.74 BRAF (0.48) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7089149 0.73 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7085451 0.73 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4553347 0.68 MAPK14 (0.76) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7087775 0.68 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7833395 0.67 PTGS2 (0.52) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7844988 0.64 PTGS2 (0.52) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9339566 0.63 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 MAPK14 1523/4885MAPK13 2251/4885MAPK12 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.